Indicate by check mark whether the registrant has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports).

Indicate by check mark whether the registrant has been subject to such filing requirements for the past 90 days.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

The number of shares outstanding of the registrant’s common stock on November ~~14, 2019,~~6, 2020, was ~~2,458,101,337.~~577,128,087.

~~The accompanying notes are an integral part of the condensed consolidated financial statements~~

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS

	For the Three Months Ended September 30, 2020			For the Three Months Ended September 30, 2019			For the Nine Months Ended September 30, 2020			For the Nine Months Ended September 30, 2019

Revenues	$	77,000		$	57,500		$	147,000		$	169,900

Cost of revenues		17,600			8,000			42,596			41,439

Gross profit		59,400			49,500			104,404			128,461

OPERATING EXPENSES
Selling, general and administrative		285,100			317,636			846,154			912,182
Amortization of patent costs		16,771			5,286			50,021			15,858
TOTAL EXPENSES		301,871			322,922			896,175			928,040

Operating loss		(242,471	)		(273,422	)		(791,771	)		(799,579	)

OTHER INCOME/(EXPENSE)
Interest expense		(289,210	)		(529,188	)		(910,236	)		(1,487,984	)
Gain (loss) on extinguishment of convertible notes		-			10,897			-			(346,395	)
Change in fair value of derivatives liabilities		926,532			(1,614,411	)		3,996,775			(657,765	)
Total other income (expense)		637,322			(2,132,702	)		3,086,539			(2,492,144	)

INCOME (LOSS) BEFORE PROVISION FOR INCOME TAXES		394,851			(2,406,124	)		2,294,768			(3,291,723	)

Provision for income taxes		-			-			-			-

NET INCOME (LOSS)	$	394,851		$	(2,406,124	)	$	2,294,768		$	(3,291,723	)

BASIC NET INCOME (LOSS) PER SHARE	$	0.00		$	(0.00	)	$	0.01		$	(0.00	)

DILUTED NET INCOME (LOSS) PER SHARE	$	0.00		$	(0.00	)	$	0.00		$	(0.00	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC		342,491,367			1,511,896,142			184,711,652			1,182,674,443

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - DILUTED		1,362,861,100			1,511,896,142			1,069,456,713			1,182,674,443

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

The accompanying notes are an integral part of these condensed consolidated financial statements.

~~UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)~~

Unless otherwise indicated, any reference to “our company”, “we”, “us”, or “our” refers to Creative Medical Technology Holdings, Inc., and as applicable to its wholly owned subsidiary, Creative Medical Technologies, Inc., a Nevada corporation (“CMT”).

Organization - Creative Medical Technology Holdings, Inc., is considered to be a commercial stage company, following the commencement of sales of disposable kits used in our Caverstem^® procedure to treat ED in the fourth quarter of 2017 and sales of our FemCelz procedure for vaginal rejuvenation that commenced in the second quarter of 2019. Our fiscal year end is December 31st. We have acquired the licensing rights for our Amniostem amniotic-based stem cell product, purchased the patent for our ED and lower back pain ~~treatments,~~procedures, filed and were granted the patent for our Ovastem™ premature ovarian failure treatment and filed patent applications for our other urological and neurological treatments.

Use of Estimates – The preparation of the financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows at September 30, ~~2019~~2020 and for the three and nine-month periods then ended have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. The operations for the three and nine-month periods ended September 30, ~~2019,~~2020, are not necessarily indicative of the operating results for the full year.

Going Concern – The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United ~~Stat~~esStates of America, which contemplate continuation of the Company as a going concern. However, during the nine-month period ended September 30, ~~2019,~~2020, the Company ~~incurred a net loss of $3,291,723~~ had negative cash flows from operating activities of $491,542 and had a working capital deficit of ~~$3,710,628.~~$3,162,874. These factors raise substantial doubt about the ability of the Company to continue as a going concern. In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of equity securities. There is no assurance that the Company will be successful in raising this additional capital or in achieving profitable operations. The unaudited condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

~~Revenue~~Risks and Uncertainties - On January 30, 2020, the World Health Organization declared the COVID-19 outbreak a “Public Health Emergency of International Concern” and on March 10, 2020, declared it to be a pandemic. Actions taken around the world to help mitigate the spread of the COVID-19 include restrictions on travel, and quarantines in certain areas, and forced closures for certain types of public places and businesses. The COVID-19 and actions taken to mitigate it have had and are expected to continue to have an adverse impact on the economies and financial markets of many countries, including the geographical area in which the Company ~~recognizes revenue as~~operates. While it is ~~earned as defined by U.S. GAAP.~~unknown how long these conditions will last and what the complete financial effect will be to the company, to-date, the Company is experiencing a reduction in revenues due to the prioritization of medical resources to address the COVID-19 outbreak. In several of our markets, all non-essential (including elective) procedures have been placed on hold. While this has a negative financial impact to our revenues, there have been the same reductions to our costs. Additionally, since the Company maintains no inventory and require nearly all of customers to pre-pay, there is no risk to receivables or inventory write-downs. The company expects existing orders temporarily on hold and continued sales, training and patient treatments will resume once the physician’s offices are back to being fully operational.

Revenue - We have adopted the new revenue recognition standards that went into effect on January 1, ~~2018.~~2019. All revenues reported in ~~2018~~2019 and beyond ~~reflects~~reflect those standards. Adoption of the standards had no effect on the Company’s revenues.

Fair Value of Financial Instruments - The Company’s financial instruments consist of cash and cash equivalents, convertible notes, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of September 30, ~~2019,~~2020, and December 31, ~~2018,~~2019, the Company didn’t have any Level 1 or 2 financial instruments. The table below reflects the results of our Level 3 fair value calculations:

Basic and Diluted Loss Per Share –The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per sh~~are~~share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. Dilutive common share equivalents include the dilutive effect of in-the-money share equivalents, which are calculated, based on the average share price for each period using the treasury stock method. Under the treasury stock method, the exercise price of an award, if any, the amount of compensation cost, if any, for future service that the Company has not yet recognized, and the estimated tax benefits that would be recorded in paid-in capital, if any, when an award is settled are assumed to be used to repurchase shares in the current period. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

The following is a summary of outstanding securities which have been included in the calculation of diluted net income per share and reconciliation of net income to net income available to common stockholders for the nine-months ended September 30, 2020.

During the three and nine-month periods ended September 30, 2019, the Company had ~~500,000~~3,333 options and ~~142,971,500~~949,810 warrants to purchase common stock outstanding. In addition, the Company has various convertible notes payable which aton September 30, 2019, are convertible into approximately ~~4,823,409,335~~32,156,062 shares of common stock. ~~During~~The effects of which were anti-dilutive due to net loss during the three and nine-month periods ended September 30, ~~2018, the Company had 500,000 options and 255,771,846 warrants to purchase common stock outstanding. The effects of the dilutive securities were anti-dilutive due to net loss during the nine-month periods ended September 30, 2019 and 2018.~~2019.

Recent Accounting Pronouncements – In February 2016, the FASB issued ASU, Leases, which requires lessees to recognize most leases on their balance sheets as a right-of-use asset with a corresponding lease liability. Lessor accounting under the standard is substantially unchanged. Additional qualitative and quantitative disclosures are also required. The Company adopted the standard effective January 1, 2019 using the cumulative-effect adjustment transition method, which applies the provisions of the standard at the effective date without adjusting the comparative periods presented. The Company adopted the following practical expedients and elected the following accounting policies related to this standard update:

~~• The option to not reassess prior conclusions related to the identification, classification and accounting for initial direct costs for leases that commenced prior to January 1, 2019~~

~~• Short-term lease accounting policy election allowing lessees to not recognize right-of-use assets and liabilities for leases with a term of 12 months or less; and~~

~~• The option to not separate lease and non-lease components for certain equipment lease asset categories such as freight car, vehicles and work equipment.~~

• The package of practical expedients applied to all of its leases, including (i) not reassessing whether any expired or existing contracts are or contain leases, (ii) not reassessing the lease classification for any expired or existing leases, and (iii) not reassessing initial direct costs for any existing leases.

The Company has inventoried all leases where the Company is a lessee as of the initial date of application and has examined other contracts with suppliers, vendors, customers and other outside parties to identify whether such contracts contain an embedded lease as defined under the new guidance. The Company’s lease population comprises an office, which is immaterial to the consolidated financial statements.

~~As a result of the above, the adoption of ASC 842 did not have a material effect on the financial statements. The Company will review for the existence of embedded leases in future agreements.~~

The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial ~~statements other than disclosed above.~~statements.

ED Patent – The Company acquired a patent from CMH.Amortization expense of $2,493 and $7,479 were recorded for the three and nine-month periods ended September 30, 2020 respectively. Amortization expense of $2,493 and ~~$7,479~~$4,986 were recorded for the three month and nine-month periods ended September 30, 2019, respectively.As of September 30, 2020, and December 31, 2019, the carrying value of the patent was ~~$63,425.~~$53,452 and $60,932, respectively. The Company expects to amortize approximately $9,972 annually through 2026 related to the patent costs.

Multipotent Amniotic Fetal Stem Cells License Agreement - In August 2016, CMT entered into a License Agreement with a University. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of September 30, 2020, and December 31, 2019, no amounts are currently due to the University.

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $293 and $882 were recorded for the three and nine-month periods ended September 30, 2020 respectively. Amortization expense of $294 and $879 were recorded for the three and nine-month periods ended September 30, 2019, respectively.As of September 30, 2020, and December 31, 2019, the carrying ~~value~~values of the patent ~~was $6,722.~~were $5,549 and $6,429, respectively. The Company expects to amortize approximately $1,172 annually through 2026 related to the patent costs.

Lower Back Patent – The Company, through ~~a newly created~~its subsidiary ~~of CMT,~~ StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for ~~$100,000, payable~~the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in ~~cash or stock.~~ November 2017. As amended, the agreement provides the following:

The patent expires on May 19, 2027 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $2,500 and $7,500 were recorded for the three and nine-month periods ended September 30, 2020. As of September 30, 2020, and December 31, 2019, the carrying value of the initial patent license was $67,500 and $75,000, respectively. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.

In November 2019, following a successful international pilot study, the Company elected to initiate commercialization of the StemSpine procedure using autologous stem cells. As a result, the Company is obligated to pay CMH $300,000 pursuant to the Patent Purchase Agreement as described above. During the nine months ended September 30, 2020, $40,000 of this amount was converted into 42,328,042 shares of the Company’s common stock. As of September 30, 2020, the remaining liability balance was $200,000. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $11,485 and $34,455 were recorded for the three and nine-month periods ended September 30, 2020. Amortization expense of $2,500 and $7,500 were recorded for the three and nine-month periods ended September 30, 2019, ~~respectively.~~ As of September 30, 2020 and December 31, 2019, the carrying value of the patent was ~~$77,500.~~$259,739 and $294,194, respectively. The ~~company expects~~Company expect to amortize approximately ~~$10,000~~$46,000 annually through 2027 related to the patent costs.

For a period of five years from the date of the first sale of any product derived from the patent, StemSpine is required to make royalty payments of 5% from gross sales of products. StemSpine has also agreed to pay royalties of 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties. In addition, StemSpine has agreed to make progress payments under the patent purchase agreement determined by whether the technology represented by the patent is tested by use of autologous cells or allogenic cells. In the case of pursuit of the technology using autologous cells, StemSpine has agreed to pay CMH $100,000 upon the signing of an agreement with a university for the initiation of an IRB clinical trial and $200,000 upon completion of the clinical trial. In the event StemSpine determines to pursue the technology using allogenic cells, StemSpine has agreed to pay CMH $100,000 upon the filing for an innovative new drug application (IND) with the FDA; $200,000 upon the dosing of the first patient in Phase 1-2 clinical trial; and $400,000 upon the dosing of the first patient in Phase 3 clinical trial. In the event StemSpine commercializes the technology via use of autologuous cells by a physician without a clinical trial, StemSpine has agreed to pay CMH $300,000. In each case StemSpine has the option to make these payments in cash or in shares of the Company’s common stock at a discount to the market price of the stock at the time of the transaction. The parties to the patent purchase agreement have agreed that in no event will the aggregate royalty payments under the agreement exceed $2,500,000.

The Company has incurred a monetary obligation to a related corporation to reimburse the cost of services provided to the Company (management and consulting) through ~~March~~December 31, ~~2020.~~2019. Each of the Company’s executive officers is employed by ~~the parent company,~~ CMH and will continue to receive his or her salary or compensation from CMH. The Company has an agreement with CMH which obligates the Company to reimburse CMH ~~$45,000~~$35,000 per month for such ~~services.~~services beginning January 2016. On November 17, 2017, the Company entered into an amended Management Reimbursement Agreement dated November 17, 2017, with Creative Medical Technologies, Inc. (“CMT”), the wholly owned subsidiary of the Company, and with Creative Medical Health, Inc., the parent of the Company (“CMH”). The ~~compensation paid~~Agreement memorializes the arrangement between the parties whereby the Company has, since January 1, 2016, reimbursed CMH $35,000 per month for the services of management and consultants employed by CMH ~~will include an allocation of~~and performing services ~~performed for CMH and~~ for the Company. The amounts are presented as a “management fee payable - related party” on the accompanying unaudited condensed consolidated balance sheets. The liability is non-interest bearing, unsecured,Company and ~~will be due upon the Company successfully raising at least $1,000,000 through the sale of equity.~~CMT. At the option of CMH, the reimbursable amounts set forth in the Agreement may be paid from time to time in shares of common stock of the Company at a price equal to a 30% discount to the lowest closing price during the 20 trading days prior to time the notice is given. The Agreement may be terminated by either party upon 30 days’ prior written notice. The agreement was amended in December 2018 to increase the monthly reimbursement from $35,000 to $45,000 effective January 1, 2019 and thereafter. During the three months ended September 30, 2020 and 2019, the Company recorded $135,000 in expense in connection with this agreement.

During the nine months ended September 30, 2020, $120,000 of the amounts accrued in connection with this agreement were converted into 21,986,841 shares of the Company’s common stock. As of September 30, 2020, and December 31, 2019, amounts due to CMH under the arrangement were ~~$0.~~$11,282 and $82, respectively.

~~On April 3, 2018,~~During the ~~Company entered into a~~nine-months ended September 30, 2020, we issued $532,850 in convertible ~~note agreement~~notes to accredited investors with ~~a third party for an aggregate principal amount~~net proceeds of ~~$110,000, for which $95,000 in proceeds were received on April 3, 2018. Under the terms~~$458,600. The notes mature during February through September of ~~the agreement, the convertible note incurs~~2022 and bear interest at ~~10% per annum and has a maturity date~~rate of ~~April 1, 2019.~~8%. The ~~convertible note is convertible upon issuance and~~notes are convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to 5 times the number of common shares the convertible note is convertible into. The Company is amortizing legal fees of $2,652 and the remaining discount of $107,348 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $110,000 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019, the Company amortized $0 and $28,027 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 11,000,000 five-year warrants to purchase common stock at ~~$0.01, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.~~

~~The~~ conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability, see Note 5. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 0 shares reserved with our transfer agent with a potential of 205,041,021 being reserved if and when the lender issues a request to our transfer agent.

In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 18%.

~~The Company has the option to redeem the convertible notes within 180 days~~prices ranging from ~~the date of issuance at 140% of the principal and interest. After 180 days the right of prepayment expires.~~

During the three and nine-month periods ended September 30, 2019, the lender converted $67,345 of principal, interest and fees into 46,767,507 common shares and $112,845 of principal, interest and fees into 66,723,648 common shares respectively.

On April 11, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $110,000, for which $100,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity 12 months from the effective date of payment. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $10,000 and the remaining discount of $100,000 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $110,000 to interest expense using the straight-line method over the term of the loan. During the three and nine-month period ended September 30, 2019, the Company amortized $0 and $30,438 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 11,000,000 five-year warrants to purchase common stock at $0.01, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 22,722,974 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.

~~The Company has the option to redeem the convertible notes within 180 days from the date of issuance at 140% of the principal and interest. After 180 days the right of prepayment expires.~~

During the three and nine-month periods ended September 30, 2019, the lender converted $48,240 of principal, interest and fees into 33,499,750 common shares and $125,240 of principal, interest and fees into 62,447,118 common shares, respectively.

~~As of September 30, 2019, the Company had fulfilled all the obligations of this note.~~

On May 14, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $108,000, for which $94,960 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of May 14, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 60% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $8,000, legal fees of $5,040 and the remaining discount of $94,960 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $108,000 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019 the Company amortized $0 and $39,649 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 3,600,000 five-year warrants to purchase common stock at $0.025, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2018, there were 0 ~~shares reserved with our transfer agent with a potential of~~ 0 ~~being reserved if and when the lender issues a request to our transfer agent.~~

~~In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including principal and accrued unpaid interest. In addition, the default interest rate would increase to 24%.~~

During the three and nine-month periods ended September 30, 2019, the lender converted $0 of principal, interest and fees into 0 common shares and $94,826 of principal, interest and fees into 22,494,347 common share~~s respectively.~~

~~As of September 30, 2019, the Company had fulfilled all the obligations of this note.~~

On September 20, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $183,250, for which $100,000 in proceeds were received and the remaining balances of two convertible notes were rolled over. At the time of combination, the total carrying amount outstanding under the prior notes was $211,570. In connection, with the agreement, the lender was paid $139,352, principal of $69,676 rolled into the new note and a gain of $2,542 was recorded within interest expense. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of September 20, 2019. The convertible note is convertible at any time after 31 days after the closing date and convertible into shares of the Company’s stock at a conversion price equal to 65% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $13,574 and the remaining discount of $169,676 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $183,250 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019 the Company amortized $0 and $132,040 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 1,247,618 five-year warrants to purchase common stock at $0.088, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 0 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.

The Company has the option to redeem the note, in whole, up to 30 days from the date of issuance with no interest, on issuance discount, fees or pre-payment penalties. After 30 days the right of prepayment expires.

During the three and nine-month periods ended September 30, 2019, the lender converted $0 of principal, interest and fees into 0 common shares and $191,282 of principal, interest and fees into 38,606,150 common shares respectively.

~~As of September 30, 2019, the Company had fulfilled all the obligations of this note.~~

On September 20, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $183,250, for which $169,676 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of September 20, 2019. The convertible note is convertible at any time after 31 days after the closing date and convertible into shares of the Company’s stock at a conversion price equal to 65% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $13,574, legal fees of $8,363 and the remaining discount of $161,313 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $183,250 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019, the Company amortized $41,168 and $132,040 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 1,247,618 five-year warrants to purchase common stock at $0.088, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 11 shares reserved with our transfer agent with a potential of 875,298,605 being reserved if and when the lender issues a request to our transfer agent.

In the event of default that is either (A) demanded (if demand or notice is required to create an Event of Default), (B) otherwise due, or (C) paid in full, whichever is lowest, multiplied by the VWAP on the date the Mandatory Default Amount is either (x) demanded, (y) due, or (z) paid in full, whichever is highest, or (ii) 120% of the outstanding principal amount of this Note, plus, (b) all other amounts, costs, expenses and liquidated damages due in respect of the Note.

The Company has the option to redeem the note, in whole, up to 30 days from the date of issuance with no interest, on issuance discount, fees or pre-payment penalties. From 31 through 170 days, the Company has the option to redeem the note at the default amount stated above. After 170 days the right of prepayment expires.

During the three and nine-month periods ended September 30, 2019, the lender converted $66,075 of principal, interest and fees into 98,586,106 common shares and $103,075 of principal, interest and fees into 113,565,864 common shares respectively.

On September 20, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $183,250, for which $169,676 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of September 20, 2019. The convertible note is convertible at any time after 31 days after the closing date and convertible into shares of the Company’s stock at a conversion price equal to 65% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $13,574, legal fees of $8,363 and the remaining discount of $161,313 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $183,250 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019 the Company amortized $41,168 and $132,040 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 1,247,618 five-year warrants to purchase common stock at $0.088, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 0 shares reserved with our transfer agent with a potential of 1,683,165,057 being reserved if and when the lender issues a request to our transfer agent.

~~During the three and nine-month periods ended September 30, 2019, the lender converted $16,250 of principal, interest and fees into 25,000,000 common shares.~~

On November 15, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $108,000, for which $100,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of November 15, 2019. The convertible note is convertible at any time after 31 days after the closing date and convertible into shares of the Company’s stock at a conversion price equal to 70% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount and other transaction-related expenses of $19,065 and the remaining discount of $74,579 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $93,644 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019, the Company amortized $0 and $70,041 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 1,985,294 five-year warrants to purchase common stock at $0.0272, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 46,189,234 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.

The Company has the option to redeem the note, in whole, up to 30 days from the date of issuance with no interest, on issuance discount, fees or pre-payment penalties. From 31 through 170 days, the company has the option to redeem the note at the default amount stated above. After 170 days the right of prepayment expires.

During the three and nine-month periods ended September 30, 2019, the lender converted $0 of principal, interest and fees into 0 common shares and $112,267 of principal, interest and fees into 42,483,073 common shares respectively.

~~As of September 30, 2019, the Company had fulfilled all the obligations of this note.~~

On November 15, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $108,000, for which $100,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of November 15, 2019. The convertible note is convertible at any time after 31 days after the closing date and convertible into shares of the Company’s stock at a conversion price equal to 70% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount and other transaction-related expenses of $14,040 and the remaining discount of $83,249 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $97,289 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019 the Company amortized $24,522 and $60,506 to interest expense respectively. As of September 30, 2019, a discount of $12,261 remained. At no additional cost, we issued to the note holder 1,985,294 five-year warrants to purchase common stock at $0.0272, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 0 shares reserved with our transfer agent with a potential of 990,438,200 being reserved if and when the lender issues a request to our transfer agent.

The Company has the option to redeem the note, in whole, up to 30 days from the date of issuance with no interest, on issuance discount, fees or pre-payment penalties. From 31 through 170 days, the company has the option to redeem the note at the default amount stated above. After 170 days the right of prepayment expires.

On November 15, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $108,000, for which $100,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 7% per annum and has a maturity date of November 15, 2019. The convertible note is convertible at any time after 31 days after the closing date and convertible into shares of the Company’s stock at a conversion price equal to 70% of the lowest trading price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to three times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $14,040 and the remaining discount of $83,249 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $97,289 to interest expense using the straight-line method over the term of the loan. During the three and nine-month periods ended September 30, 2019 the Company amortized $36,783 and $72,767 to interest expense respectively. As of September 30, 2019, a discount of $0 remained. At no additional cost, we issued to the note holder 1,985,294 five-year warrants to purchase common stock at $0.0272, subject to adjustment if we issue securities at less than the exercise price. The warrants are exercisable on a cashless basis.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 7 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.

The Company has the option to redeem the note, in whole, up to 30 days from the date of issuance with no interest, on issuance discount, fees or pre-payment penalties. From 31 through 170 days, the company has the option to redeem the note at the default amount stated above. After 170 days the right of prepayment expires.

~~During the three and nine-month periods ended September 30, 2019, the lender converted $114,409 of principal, interest and fees into 120,047,983 common shares.~~

~~As of September 30, 2019, the Company had fulfilled all the obligations of this note.~~

On November 15, 2018, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $168,300, for which $150,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of April 1, 2019. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 71% of the average of the 2two lowest ~~trading~~traded prices or the lowest trade price of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is ~~required at all times~~amortizing the discount due to ~~reserve shares of the Company’s common stock equal to 6 times the number of common shares the convertible note is convertible into. The Company is amortizing an~~derivative liabilities and on-issuance discount ~~of $15,300, legal fees of $3,000 and the remaining discount of $92,917 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $111,217~~totaling $532,850 to interest expense using the straight-line method over the ~~term~~original terms of the ~~loan.~~ loans.

During the ~~three~~nine-months ended September 30, 2020 and ~~nine-month periods~~2019, the Company amortized $804,898 and $1,350,982 respectively, to interest expense. As of September 30, 2020, total discounts of $288,851 remained for which will be expensed through February 2021.

During the nine-months ended September 30, 2020, the Company issued an aggregate of 388,932,620 shares upon the conversion of $1,033,418 of outstanding principal, interest and fees on existing, outstanding notes. During the nine-months ended September 30, 2019, the Company ~~amortized $0~~issued an aggregate of 7,507,173 shares upon the conversion of $1,358,088 of outstanding principal, interest and ~~$83,184 to interest expense respectively. As~~fees on existing, outstanding notes and 531,247 shares upon the cashless exercise of 594,051 warrants.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance,2020, the Company ~~anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number~~extinguished $23,000 of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 152,439,592 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.

~~In the event of default, the holder has the right to require the Company to pay an amount equal to 150% multiplied by the then outstanding entire balance of the note, including~~ principal and ~~accrued unpaid interest. In addition, the default~~ interest ~~rate would increase to 22%.~~

The Company has the option to redeem the convertible notes within 30 days from the date of issuance at 100% of the principal and interest; between 31 and to 60 days from the date of issuance at 105% of the principal and interest; between 61 and to 90 days from the date of issuance at 110% of the principal and interest; between 91 and to 120 days from the date of issuance at 115% of the principal and interest; between 121 and to 150 days from the date of issuance at 120% of the principal and interest; between 151 and to 180 days from the date of issuance at 125% of the principal and interest; and after 180 days the right of prepayment expires.

~~On January 18, 2019 the Company retired the note~~ with ~~a payment of $187,484 to the note holder. A derivative liability gain of $59,519 and a premium loss of $19,154 were recorded to reflect the retirement of the loan.~~

On January 30, 2019, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $140,800, for which $125,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 10% per annum and has a maturity date of January 1, 2020. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 71% of the 2 lowest trading prices of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to 6 times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $12,800, legal fees of $3,000 and the remaining discount of $113,495 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $129,295 to interest expense using the straight-line method over the term of the loan.no pre-payment premiums. During the ~~three and nine-month periods~~nine-months ended September 30, 2019, the Company ~~amortized $75,806 and $129,295 respectively. As~~incurred $38,343 in pre-payment premiums associated with the extinguishment of ~~September 30, 2019, a discount of $0 remained.~~

~~The conversion price is subject to adjustment~~$246,168 in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 88,783,544 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.

~~During the three and nine-month periods ended September 30, 2019, the lender converted $120,109 of principal,~~that was recorded as interest ~~and fees into 105,683,673 common shares and the Company paid down $25,811 of principal.~~expense.

As of September 30, ~~2019, the Company had fulfilled all the obligations of this note.~~

On February 28, 2019, the Company entered into three separate Exchange Agreements with the holders of Common Stock Purchase Warrants issued by the Company in September 2018 and November 2018. Under each Exchange Agreement, the Company issued a convertible promissory note in the principal amount of $100,000 to the Warrant Holder party to such Exchange Agreement in exchange for the cancellation of Common Stock Purchase Warrants held by such Warrant Holder, initially exercisable for an aggregate of 3,232,912 shares of the Company’s common stock. The exchanges were effected pursuant to Sections 3(a)(9) and 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder. The Company is required at all times to reserve shares of the Company’s common stock equal to 3 times the number of common shares the convertible note is convertible into.

~~Each Exchange Note matures on February 28,~~ 2020, bears interest at a rate of 8% per annum, and beginning 31 days after the closing date, is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the Market Price of the common stock. “Market Price” as defined in each Exchange Note means the average of the two lowest “VWAPs” (as defined) of the Company’s common stock during the 15 trading days preceding the applicable conversion date.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 25,000,000 shares reserved with our transfer agent with a potential of 1,464,079,309 being reserved if and when the lender issues a request to our transfer agent.

The Company has the option to redeem the note, in whole, up to 30 days from the date of issuance with no interest, on issuance discount, fees or pre-payment penalties. From 31 through 170 days, the company has the option to redeem the note at the default amount stated above. After 170 days the right of prepayment expires.

During the three and nine-month periods ended September 30, 2019, the lenders converted $50,700 of principal, interest and fees into 130,000,000 common shares and $153,034 of principal, interest and fees into 167,940,031 common shares respectively.

On March 1, 2019, the Company completed the sale of Convertible Notes (“Notes”) and Common Stock Purchase Warrants (“Warrants”) to four institutional investors (the “Investors”) pursuant to a Securities Purchase Agreement between the Company and the Investors (the “Purchase Agreement”) dated as of February 19, 2019. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

Pursuant to the Purchase Agreement, for a purchase price of $100,000, each Investor purchased a Note in the principal amount of $110,000 and a Warrant to purchase 1,334,951 shares of common stock. Each Note matures on March 1, 2020, bears interest at a rate of 8% per annum, and beginning 31 days after the closing date, is convertible into shares of the Company’s common stock at a conversion price equal to 65% of the Market Price of the common stock. “Market Price” as defined in each Exchange Note means the average of the two lowest “VWAPs” (as defined) of the Company’s common stock during the 15 trading days preceding the applicable conversion date. In addition, the Notes are subject to covenants, events of defaults and other terms and conditions customary in transactions of this nature.

The Company is required at all times to reserve shares of the Company’s common stock equal to 3 times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $40,000, legal fees of $29,110 and the remaining discount of $370,890 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $440,000 to interest expense using the straight-line method over the term of the loan. During the three- and nine-month periods ended September 30, 2019, the Company amortized $110,600 and $256,064 respectively. As of September 30, 2019, a discount of $183,936 remained.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 130,000,000 shares reserved with our transfer agent with a potential of 2,523,330,819 being reserved if and when the lender issues a request to our transfer agent.

Each Warrant is exercisable for a five-year period at an initial exercise price of $0.0206 per share, subject to anti-dilution adjustment in the event of stock dividends, stock splits and other specified events.

~~During the three and nine-month periods ended September 30, 2019, the lenders converted $119,724 of principal, interest and fees into 234,302,572 common shares.~~

On March 8, 2019, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $91,300, for which $80,300 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 12% per annum and has a maturity date of March 8, 2020. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 71% of the 2 lowest trading prices of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to 6 times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $8,300, legal fees of $2,700 and the remaining discount of $60,762 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $71,762 to interest expense using the straight-line method over the term of the loan. During the three- and nine-month periods ended September 30, 2019, the Company amortized $49,163 and $71,762 respectively. As of September 30, 2019, a discount of $0 remained.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 8,360,418 shares reserved with our transfer agent with a potential of 0 being reserved if and when the lender issues a request to our transfer agent.

~~During the three and nine-month periods ended September 30, 2019, the lenders converted $95,030 of principal, interest and fees into 126,781,478 common shares.~~

~~As of September 30, 2019, the Company had fulfilled all the obligations of this note.~~

On June 20, 2019, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $133,000, for which $114,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 11% per annum and has a maturity date of June 20, 2020. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 66% of the lowest traded price of the Company’s common stock during the previous 20 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to 4 times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $13,000 legal fees of $6,000 and the remaining discount of $114,000 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $133,000 to interest expense using the straight-line method over the term of the loan. During the three and six months ended September 30, 2019 the Company amortized $33,432 and $37,066 respectively. As of September 30, 2019, a discount of $95,934 remained.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 20,151,000 shares reserved with our transfer agent with a potential of 1,661,677,377 being reserved if and when the lender issues a request to our transfer agent.

The Company has the option to redeem the convertible notes within 60 days from the date of issuance at 120% of the principal and interest; between 61 and to 120 days from the date of issuance at 130% of the principal and interest; between 121 and to 180 days from the date of issuance at 140% of the principal and interest; and after 180 days the right of prepayment expires.

On July 2, 2019, the Company completed the sale of 8% Original Issue Discount Senior Convertible Notes and Common Stock Purchase Warrants to two institutional investors pursuant to a Securities Purchase Agreement between the Company and the Investors dated as of July 2, 2019. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

Pursuant to the Purchase Agreement, for a purchase price of $50,000, each Investor purchased a Note in the principal amount of $54,000.00 and a Warrant to purchase 5,555,555 shares of common stock. Each Note matures on June 27, 2020, bears interest at a rate of 8% per annum, and is convertible into shares of the Company’s common stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the 15 trading days preceding the applicable conversion date. In addition, the Notes are subject to covenants, events of defaults and other terms and conditions customary in transactions of this nature.

The Company is required at all times to reserve shares of the Company’s common stock equal to 3 times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $8,000, legal fees of $5,000 and the remaining discount of $95,000 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $108,000 to interest expense using the straight-line method over the term of the loan. During the three- and nine-month periods ended September 30, 2019, the Company amortized $26,850. As of September 30, 2019, a discount of $81,150 remained.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 0 shares reserved with our transfer agent with a potential of 1,101,304,110 being reserved if and when the lender issues a request to our transfer agent.

In the event of default that is either (A) demanded (if demand or notice is required to create an Event of Default), (B) otherwise due, or (C) paid in full at the Holder’s discretion, (i) the conversion of the outstanding principal amount of this Note, plus all accrued and unpaid interest, converted at the Conversion Price or (ii) the payment 135% of the outstanding principal amount of this Note and accrued and unpaid interest hereon, in addition to, for both (i) and (ii), above, the payment of all other amounts, costs, expenses and liquidated damages due in respect of this Note. Additionally, at the Holder’s discretion, upon the occurrence of an Event of Default, without any further action on the part of the Company or the Holder, the Conversion Price shall be reduced to an amount equivalent to fifty percent (50%) of the lowest traded price during the fifteen (15) Trading Days immediately prior to the applicable Conversion Date.

Each Warrant is exercisable for a five-year period at an initial exercise price of $0.0045 per share, subject to anti-dilution adjustment in the event of future sales of equity by the Company below the then exercise price, stock dividends, stock splits and other specified events.

On July 29, 2019, the Company completed the sale of 8% Original Issue Discount Senior Convertible Notes and Common Stock Purchase Warrants to three institutional investors pursuant to a Securities Purchase Agreement between the Company and the Investors dated as of July 29, 2019. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

Pursuant to the Purchase Agreement, for a purchase price of $75,000, each Investor purchased a Note in the principal amount of $81,000 and a Warrant to purchase 4,807,695 shares of common stock. Each Note matures on July 28, 2020, bears interest at a rate of 8% per annum, and is convertible into shares of the Company’s common stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the 15 trading days preceding the applicable conversion date. In addition, the Notes are subject to covenants, events of defaults and other terms and conditions customary in transactions of this nature.

The Company is required at all times to reserve shares of the Company’s common stock equal to 3 times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $18,000, legal fees of $2,015 and the remaining discount of $222,985 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $243,000 to interest expense using the straight-line method over the term of the loan. During the three- and nine-month periods ended September 30, 2019, the Company amortized $41,829. As of September 30, 2019, a discount of $201,171 remained.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company anticipates that it will account for conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 302,433,249 shares reserved with our transfer agent with a potential of 2,463,553,973 being reserved if and when the lender issues a request to our transfer agent.

Each Warrant is exercisable for a five-year period at an initial exercise price of $0.0039 per share, subject to anti-dilution adjustment in the event of future sales of equity by the Company below the then exercise price, stock dividends, stock splits and other specified events.

On July 24, 2019, Timothy Warbington, the Company’s Chief Executive Officer, made an unsecured loan to the Company in the principal amount of $50,000. The loan is payable on the earlier of demand and July 23, 2020, and bears interest at the rate of 2.13% per annum.

~~As of September 30, 2019, the Company had fulfilled all the obligations of this note.~~

On August 22, 2019, the Company entered into a convertible note agreement with a third party for an aggregate principal amount of $69,300, for which $63,000 in proceeds were received. Under the terms of the agreement, the convertible note incurs interest at 8% per annum and has a maturity date of March 8, 2020. The convertible note is convertible upon issuance and convertible into shares of the Company’s stock at a conversion price equal to 71% of the 2 lowest trading prices of the Company’s common stock during the previous 15 trading days preceding the conversion date. The Company is required at all times to reserve shares of the Company’s common stock equal to 5 times the number of common shares the convertible note is convertible into. The Company is amortizing an on-issuance discount of $6,300, legal fees of $3,000 and the remaining discount of $60,000 due to the recording of a derivative liability as discussed in Note 5. The Company is amortizing the total discount of $69,300 to interest expense using the straight-line method over the term of the loan. During the three- and nine-month periods ended September 30, 2019, the Company amortized $7,384. As of September 30, 2019, a discount of $61,916 remained.

The conversion price is subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions and any issuances of securities below the conversion price of the convertible note. On the date of issuance, the Company accounted for the conversion feature as a derivative liability. Derivative accounting applies as the conversion price is variable and does not have a floor as to the number of common shares in which could be converted. Thus, if the convertible note is not repaid prior to the note being converted significant pressure may be put on the Company’s stock price and additional dilution of current shareholders may take place. As of September 30, 2019, there were 25,000,000 shares reserved with our transfer agent with a potential of 984,399,614 being reserved if and when the lender issues a request to our transfer agent.

In connection with convertible notes payable, the Company records derivative liabilities for the conversion feature. In addition, the Company has warrants for which the exercise prices reset upon future events. These warrants are also considered to be derivative liabilities. The derivative liabilities are valued on the date the convertible note payable become convertible and revalued at each reporting period. The warrants are valued on the date of issuance and revalued at each reporting period. During the ~~nine months~~nine-months ended September 30, ~~2019,~~2020, the Company recorded initial derivative liabilities of ~~$1,322,715~~$852,523 based upon the following Black-Scholes option pricing model average assumptions: an exercise price of ~~$0.0007~~$0.0017 to ~~$0.0206~~$0.0158 our stock price on the date of grant of ~~$0.0007~~$0.0034 to ~~$0.0185,~~$0.0365, expected dividend yield of 0%, expected volatility of ~~77%~~103.96% to ~~100%~~131.89%, risk free interest rate of ~~1.56%~~0.16% to ~~2.55%~~1.62% and expected terms ~~ranging from~~of 1.0 ~~to 5.0 years.~~year. Upon initial valuation, the derivative liabilities exceeded the face values certain of the convertible notes payable by approximately ~~$306,463,~~$393,923, which was recorded as a day one loss in derivative liability.

On September 30, ~~2019,~~2020, the derivative liabilities were revalued at ~~$2,554,160~~$1,570,971 resulting in a ~~loss~~gain of ~~$1,432,412~~$1,017,603 related to the change in fair market value of the derivative ~~liabilities.~~liabilities during the three months ended September 30, 2020. The derivative liabilities were revalued using the Black-Scholes option pricing model with the following average assumptions: an exercise price of ~~$0.0004~~$0.0015 to ~~$0.0250,~~$3.0900, our stock price on the date of valuation ($~~0.0008)~~0.0029), expected dividend yield of 0%, expected volatility of ~~93%~~102.64% to ~~100%~~103.79%, risk-free interest rate of ~~1.56%~~0.11%, and an expected terms ranging from 0.5 to ~~4.8~~3.8 years.

1712

Table of Contents

In connection with convertible notes converted, as disclosed in Note 5,4, the Company reclassed derivative liabilities with a fair value of ~~$782,225 and $2,365,291~~$1,738,731 to additional paid-in capital for the ~~three- and~~ nine-month ~~periods~~period ended September 30, ~~2019 respectively.~~2020. The Company revalued the derivative liabilities at each conversion date recording the pro-rata portion of the derivative liability as compared to the portion of the convertible note converted to the pre-conversion carrying value to additional paid-in capital.

Most of the Company’s convertible notes payable contain adjustable conversion terms with significant discounts to market. As of September 30, ~~2019,~~2020, the Company’s convertible notes payable are potentially convertible into an aggregate of approximately ~~4.8 billion~~813 million shares of common stock. In addition, due to the variable conversion prices on some of the Company’s convertible notes, the number of common shares issuable is dependent upon the traded price of the Company’s common stock.

From ~~March 2017~~January 2020 through September ~~2019,~~2020, the Company issued ~~129,575,745~~11,630,953 warrants ~~to multiple parties associated~~in connection with ~~the issuance of~~services and convertible ~~notes. The issued warrants expire 5 years from the date of issuance and have anti-dilution and re-pricing features.~~notes payable.

The fair value of each warrant is estimated using the Black-Scholes valuation ~~model.~~model on the date of issuance and if needed at each period end. Assumptions used in calculating the fair value atduring the nine months ended September 30, ~~2019~~2020 were as follows:

Since the expected life of the warrants was greater than the Company’s historical stock information available, the Public Company determined the expected volatility based on price fluctuations of comparable public companies.

The issuances, exercises and pricing re-sets during the ~~six~~nine months ended September 30, ~~2019,~~2020, are as follows:

During the three and nine months ended, the Company expensed $68,242 to selling, general and administrative expense related to warrants issued in connection with marketing services for which there is no further performance.

In accordance with ASC 855, management reviewed all material events through ~~August~~November 13, ~~2019,~~2020, for these financial statements and there are no material subsequent events to report, except as follows:

On October 11, 2019, the Company completed the sale of 8% Original Issue Discount Senior Convertible Notes (“Notes”) to three institutional investors pursuant to a Securities Purchase Agreement between the Company and the investors. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder. Pursuant to the Purchase Agreement, for an aggregate purchase price of $275,000, the Investors purchased Notes in the aggregate principal amount of $297,000. Each Note matures on October 11, 2020, bears interest at a rate of 8% per annum, and is convertible into shares of the Company’s common stock at a conversion price equal to 60% of the lowest traded price of the Company’s common stock during the 15 trading days preceding the applicable conversion date.Conversion Notice

The Purchase Agreement requires the Company to file a preliminary information statement with the Securities and Exchange Commission within 30 days following the closing to effect a reverse split of the Company’s Common Stock at a ratio of between one-for-25 and one-for-75, and to cause the Reverse Split to become effective no later than December 30, 2019. In addition, the Notes are subject to covenants, events of defaults and other terms and conditions customary in transactions of this nature.

During October and November of ~~2019,~~2020, we issued ~~287,103,971~~104,369,580 shares of common stock for the conversion of ~~$77,061~~$148,100 in convertible notes.

1813

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, ~~2018,~~2019, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on urology, orthopedics and neurology using adult stem cell treatments.

We currently conduct substantially all of our commercial operations through Creative Medical Technologies, Inc. (“CMT”) our wholly-owned subsidiary. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 15 locations in the United States and Europe.

We are ~~considered to be a~~currently focused on expanding the commercial ~~stage company, following the commencement~~sale and use of ~~sales of stem cell disposable kits used in our Caverstem procedure to treat ED~~CaverStem® and FemCelz® by physicians in the ~~fourth quarter of 2017~~United States, Europe and South America, and commercializing our ~~FemCelz procedure~~StemSpine® treatment for ~~vaginal rejuvenation. Our fiscal year end is December 31st. We have acquired the licensing rights for our Amniostem amniotic-based stem cell, purchased the patent for our ED and~~ lower back ~~pain treatments, and filed patent applications for~~pain. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products that utilize our ~~neurological treatments.~~proprietary intellectual property.

Our principal executive offices are located at 211 E Osborn Road, Phoenix, AZ 85012.

During the first ~~nine months~~nine-months of ~~2019,~~2020, we issued ~~$1,275,400~~$532,850 in convertible notes with net proceeds of ~~$1,047,295~~$458,600 to accredited investors. ~~In addition, we issued $300,000 in convertible notes in exchange for the extinguishment of 9,698,736 warrants.~~

During the nine-month period ending September 30, ~~2019,~~2020, we incurred interest expense of ~~$1,487,984~~$105,338 arising from the third-party notes of ~~$1,532,614.~~$1,197,354.

We commenced marketing disposable stem cell ~~separation~~concentration kits for the ~~Caverstem® ED~~CaverStem® erectile dysfunction treatment in the fourth quarter of ~~2017. We commenced marketing disposable stem cell separation kits for~~2017 and the ~~FemCelz™ procedure to treat~~FemCelz® female sexual ~~disfunction~~dysfunction treatment in March of 2019. The Company also announced the commercialization of the StemSpine procedure for lower back pain in the fourth quarter of ~~2018.~~2019. We also continued to make progress towards filing an Innovative New Drug (IND) application for the Amniostem universal donor stem cell to treat stroke and neurodegenerative conditions. For the next 12 months our plan of operations is to continue to expand the market ~~our disposable kits, publish~~for the ~~result of~~CaverStem® and FemCelz® procedures, launch the ~~combined UCLA/LABiomed clinical trial and post-marketing patient results~~StemSpine procedure, file an IND application on Amniostem and partner with leading researchers ~~on investigator-initiated trials~~ to ~~advance our neurological programs.~~initiate the Amniostem trial. As of September 30, ~~2019,~~2020, we had approximately ~~$158,236~~$39,000 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least ~~December 2019.~~August 2020. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable stem cell concentration kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales ~~efforts and complete our ED clinical trial.~~efforts. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Results of Operations – For the ~~Three-Month~~Three-month Period Ended September 30, ~~2019~~2020 and ~~2018~~2019

Gross Revenue. We generated ~~$57,500~~$77,000 gross revenue for the three-month period ended September 30, ~~2019,~~2020, in comparison with ~~$52,400~~$57,500 for the comparable quarter a year ago. The increase of ~~$5,100~~$19,500 or ~~10%~~34% reflects the ~~increased sales~~return to a growth trajectory as the effects of the ~~disposable kits for the Caverstem and FemCelz procedures.~~COVID-19 pandemic begin to dimmish.

Cost of Goods Sold. We generated ~~$8,000~~$17,600 cost of goods sold for the three-month period ended September 30, ~~2019,~~2020, in comparison with ~~$36,395~~$8,000 for the comparable quarter a year ago. The ~~decrease~~increase of ~~$28,395~~$9,600 or ~~78% reflects~~120% is due to the increased revenues and slightly lower ~~per unit cost of the Caverstem 2.0 and FemCelz disposable kits and fewer kits used in training.~~gross margins as incentives were offered to new physician providers.

Gross Profit/(Loss). We generated ~~$49,500~~$59,400 in gross profit for the three-month period ended September 30, ~~2019,~~2020, in comparison with ~~$16,005~~$49,500 for the comparable quarter a year ago. The increase of ~~$33,495~~$9,900 or ~~209%~~20% is ~~primarily driver by lower per unit costs of~~due to the ~~disposable kits.~~increased revenues and reduced margins referenced above.

General and Administrative Expenses.General and administrative expenses for the three-month period ended September 30, ~~2019,~~2020, totaled ~~$317,636,~~$301,871 in comparison with ~~$282,670,~~322,922, for the comparable quarter a year ago. The ~~increase~~decrease of ~~$34,966,~~$21,051 or ~~12%~~7% is primarily due to ~~an increase~~a decrease of ~~$26,718~~$23,898 in ~~marketing expenses offset by decreased~~ travel ~~expenses associated with the commercialization of the Caverstem and FemCelz procedures.~~expenses.

Research and D~~evelopment~~Development Expenses.~~Research~~There were no research and development expenses for the three-month period ended September 30, ~~2019, totaled $0 in comparison with $2,884, for the comparable quarter a year ago. The decrease of $2,884, or 100% is due to a reduction of $2,884 in laboratory expenses.~~

~~Other Income / Expense.~~ Other expense for the three-month period ended September 30, 2019, totaled $2,132,702 in comparison with other expense of $1,296,185, for the comparable quarter a year ago. The increase of $836,517, or 65% is primarily due to an increased loss in the change of the fair value of derivative liabilities of $695,2642020, and ~~a $152,150 increase in interest expense associated with an increase in the debt balance.~~

~~Net Loss.~~ ~~For the reasons stated above, our net loss for the three-month period ended September 30, 2019, totaled $2,406,124 in comparison to $1,571,020,~~ for the comparable quarter a year ago.

Other Income / Expense. Other income for the three-month period ended September 30, 2020, totaled $637,322 in comparison with other expense of $2,132,702, for the comparable quarter a year ago. The increased income of $2,770,024, or 130% is primarily due to a gain in the fair value of derivative liabilities of $926,532, and a $239,978 reduction in interest expense.

Net Income/Loss. For the reasons stated above, our net income for the three-month period ended September 30, 2020, totaled $394,851 in comparison to a loss of $2,406,124, for the comparable quarter a year ago.

Results of Operations – For the Nine-month ~~Period~~period Ended September 30, ~~2019~~2020 and ~~2018~~2019

Gross Revenue. We generated ~~$169,900~~$147,000 gross revenue for the nine-month period ended September 30, ~~2019~~2020, in comparison with ~~$66,800~~$169,900 for the comparable ~~quarter~~period a year ago. The ~~increase~~decrease of ~~$103,100~~$22,900 or ~~154%~~38% reflects the ~~increased sales~~effects of the ~~disposable kits for~~COVID-19 pandemic which caused the ~~Caverstem and FemCelz procedures.~~effective cessation of elective procedures in the United States from March through June, 2020.

Cost of Goods Sold. We generated ~~$41,439~~$42,596 cost of goods sold for the nine-month period ended September 30, ~~2019~~2020, in comparison with ~~$41,323~~$41,439 for the comparable ~~quarter~~period a year ago. The increase of ~~$116~~$1,157 or ~~0.3% reflects~~3% is due to the ~~increased sales~~effect of the ~~disposable~~COVID-19 pandemic and slightly lower gross margins as incentives such as additional complementary kits ~~for the Caverstem and FemCelz procedures offset by lower per unit costs of the disposable kits.~~were offered to new physician providers.

Gross Profit/(Loss). We generated ~~$128,461~~$104,404 in gross profit for the nine-month period ended September 30, ~~2019~~2020, in comparison with ~~$25,477~~$128,461 for the comparable ~~quarter~~period a year ago. The ~~increase~~decrease of ~~$102,984~~$24,057 or ~~404% reflects~~43% is due to the ~~increased sales of the disposable kits for the Caverstem~~lower revenues and ~~FemCelz procedures offset by lower per unit costs of the disposable kits.~~reduced margins referenced above.

General and Administrative Expenses.General and administrative expenses for the nine-month period ended September 30, ~~2019,~~2020, totaled ~~$912,182,~~$846,154, in comparison with ~~$793,216,~~$912,182, for the comparable period a year ago. The ~~increase~~decrease of ~~$118,966,~~$66,028, or ~~15%~~19% is primarily due to a ~~$79,900 increase~~decrease of $66,591 in marketing ~~and a $60,000 increase in management fees offset by a $40,500 decrease in travel~~ expenses.

Research and Development Expenses.~~Research~~There were no research and development expenses for the nine-month period ended September 30, ~~2019, totaled $0 in comparison with $10,284,~~2020, and for the comparable period a year ago. ~~The decrease of $10,284, or 100% is due to the completion of the pre-clinical research of the Amniostem~~^®.

Other Income / Expense. Other ~~expense~~income for the nine-month period ended September 30, ~~2019,~~2020, totaled ~~$2,492,144~~$3,086,539 in comparison with other expense of ~~$14,796,123,~~$2,492,144, for the comparable ~~period~~quarter a year ago. The ~~decrease~~increase of ~~$12,303,979,~~$5,578,683, or ~~83%~~224% is primarily due to ~~a reduction of $13,653,662 associated with~~an increase in the ~~change~~gain in the fair value of derivative liabilities ~~offset by an increase~~ of ~~$506,643~~$3,996,775, a $346,395 loss on extinguishment of convertible notes in 2019 and a $577,748 reduction in interest ~~expense associated with a higher debt balance~~expense.

Net Loss. For the reasons stated above, our net income for the nine-month period ended September 30, 2020, totaled $2,294,768 in comparison to a loss of $3,291,723, for the comparable period a year ago.

~~Net Loss.~~ ~~For the reasons stated above, our net loss for the nine-month period ended September 30, 2019 totaled $3,291,723 in comparison to $15,590,004, for the comparable period a year ago.~~

Our principal source of liquidity has been funds received from the sale of our common stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by third parties and revenues generated from our Caverstem ED and FemCelz vaginal ~~rejuvination~~rejuvenation procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.

Our only commitments for expenditures relate to general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED and vaginal rejuvenation treatments.

For the next 12 months our plan of operations is to market our disposable kits ~~publish the results of the combined UCLA/LABiomed clinical trial and post-marketing patient results~~ and partner with leading researchers on investigator-initiated trials to advance our neurological programs. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

Net Cash used in Operating Activities.We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was ~~$960,661~~$491,542 for the nine-month period ended September 30, ~~2019~~2020 in comparison to ~~$756,639~~$960,661 for the comparable period a year ago, ~~an increase~~a decrease of ~~$204,022~~$469,119 or ~~27%~~49%. The ~~increase~~decrease in cash used in operations was primarily related to ~~increases~~a $276,200 increase in ~~marketing expenses associated with commercialization of the Caverstem~~accounts payable and ~~FemCelz procedures combined with increased public company~~monies owed to CMH and ~~shareholder-related expenses offset by expenditure reductions~~a $31,705 increase in ~~travel~~accounts payable and ~~outside consultants~~a $20,500 decrease in accounts receivable.

Net Cash used in Investing Activities.There was no cash used in investing activities in the nine-month periods ended September 30, ~~2019~~2020 and September 30, ~~2018~~2019, respectively.

Net Cash From Financing Activities.In the nine-month period ended September 30, 2020, we raised $458,600 through the issuance of convertible debt, retired $17,000 of convertible debt and did not pay any prepayment premiums on retired convertible notes. In the nine-month period ended September 30, 2019, we raised $1,047,295 through the issuance of convertible debt, expended $194,111 to retire convertible debt, and paid $38,343 in prepayment premiums on the retired convertible notes. In the nine-month period ended September 30, 2018, we raised $1,378,072 through the issuance of convertible debt, expended $405,294 to retire convertible debt, and paid $57,004 in prepayment premiums on the retired convertible notes. The ~~$100,933~~$373,241 or ~~11%~~46% decrease in cash flows from financing activities were primarily related to ~~timing~~reduced levels of ~~our~~ financing ~~activities.~~and lower loan repayments.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of September 30, ~~2019,~~2020, the Company had ~~$158,236~~$39,000 of available cash and a working capital deficit of ~~$3,710,628.~~$3,162,874. For the nine-month period ended September 30, ~~2019,~~2020, the Company had ~~$169,900~~$147,000 in revenue, ~~$799,579~~$791,771 in operating loss and used net cash for operating activities of ~~$960,661.~~$491,542. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2020.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule ~~13(a)~~15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “~~Exchange Act~~”“Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report~~are~~ were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. In April 2016, the Company entered into an agreement with a third party to perform banking services. The banking services did not materialize and thus the Company cancelled the agreement in June 2016. The Company and the third party are currently in a dispute as to fees under the agreement. The Company believes no consideration is due as the services were not performed. Any proposed litigation or equivalent will be vigorously defended for which the Company expects to prevail. ~~The dispute is currently being litigated in an New York Supreme Court.~~ As of the date of these financial statements the Company has not recorded a loss provision as the amount is not probable.

During the nine-months ended September 30, ~~2019,~~2020, we issued convertible promissory notes in the face amount of ~~$1,575,400~~$532,850 to multiple lenders for which we received proceeds of ~~$1,047,295 and the extinguishment of 9,698,736 warrants.~~$458,600. The notes bear interest ~~ranging from 2% to 11%~~of 8% which would increase up to 24% in the event of default and have maturity dates ~~ranging~~ from February ~~2020~~ through ~~August 2020.~~June, 2021. The notes are convertible at rates ranging from 60% to 71% of either the average of the two lowest traded prices of our common stock during the prior 15 trading days preceding the conversion date or the average of the two lowest ~~volume weighted average~~traded prices ~~(VWAP)~~ of our common stock during the prior 15 trading days preceding the conversion date. We have the option to redeem the notes, in whole or in part, on ~~$553,300~~$364,550 of the face amount of the issued convertible promissory notes for premiums ranging from 0% to ~~130%~~125% of the outstanding principle and interest up to 180 days from the date of issuance. After 180 days the right of repayment expires.

2220

Table of Contents

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Nevada		87-0622284
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

~~3008 W. Lupine,~~ 211 E Osborn Road, Phoenix, AZ		~~85029~~ 85012
(Address of principal executive offices)		(Zip Code)

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
N/A		N/A		N/A

Large accelerated filer	¨ ☐	Accelerated filer	¨ ☐
Non-accelerated filer	x ☐	Smaller reporting company	x ☒
		Emerging growth company	x ☒

			Page Number
PART I – FINANCIAL INFORMATION		1

Item 1.	Financial Statements	1

	Unaudited Condensed Consolidated Balance Sheet	1	3

	Unaudited Condensed Consolidated Statement of Operations	2	4

	Unaudited Condensed Consolidated Statements of Cash Flows	3	5

	Unaudited Condensed Consolidated Statement of ~~Stockholder'~~Stockholder’ (deficit)	4	6

	Notes to Unaudited Condensed Consolidated Financial Statements	5	8

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	19	14

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	22	18

Item 4.	Controls and Procedures	22	18

PART II – OTHER INFORMATION		22

Item 1.	Legal Proceedings	22	19

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		19

22Item 6.	Exhibits		20

	September 30, 2019			December 31, 2018
ASSETS
CURRENT ASSETS
Cash	$	158,236		$	304,056
Accounts receivable		24,500			9,600
Total Current Assets		182,736			313,656

OTHER ASSETS
Licenses, net of amortization		147,647			163,505
TOTAL ASSETS	$	330,383		$	477,161

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Accounts payable	$	323,801		$	331,838
Accrued expenses		65,275			21,640
Management fee payable - related party		53,082			198,082
Convertible notes payable, net of discount of $636,368 and $792,994, respectively		896,246			682,056
Advances from related party		10,800			10,800
Derivative liabilities		2,544,160			3,227,382
Total Current Liabilities		3,893,364			4,471,798

TOTAL LIABILITIES		3,893,364			4,471,798

Commitments and contingencies

STOCKHOLDERS' DEFICIT
Preferred stock, $0.001 par value, 7,000,000 and 7,000,000 shares authorized, no shares issued and outstanding at September 30, 2019 and December 31, 2018		-			-
Series A preferred stock, $0.001 par value, 3,000,000 shares authorized, 3,000,000 shares issued and outstanding at September 30, 2019 and December 31, 2018		3,000			3,000
Common stock, $0.001 par value, 3,000,000,000 and 3,000,000,000 shares authorized; 2,109,074,289 and 903,311,370 issued and 2,108,474,289 and 902,711,370 outstanding at September 30, 2019 and December 31, 2018, respectively		2,108,474			902,711
Additional paid-in capital		14,698,601			12,180,985
Accumulated deficit		(20,373,056	)		(17,081,333	)
TOTAL STOCKHOLDERS' DEFICIT		(3,562,981	)		(3,994,637	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	330,383		$	477,161

~~Nevada~~CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.		~~87-0622284~~
(Exact name of registrant as specified in its charter)

		CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
~~Item 6.~~UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
~~Exhibits~~	22

	For the Three Months Ended September 30, 2019			For the Three Months Ended September 30, 2018			For the Nine Months Ended September 30, 2019			For the Nine Months Ended September 30, 2018
Revenues	$	57,500		$	52,400		$	169,900		$	66,800

Cost of revenues		8,000			36,395			41,439			41,323

Gross profit		49,500			16,005			128,461			25,477

OPERATING EXPENSES
Research and development		-			2,884			-			10,284
General and administrative, including stock-based compensation of $0, $0, $0, and $1,877, respectively		317,636			282,670			912,182			793,216
Amortization of patent costs		5,286			5,286			15,858			15,858
TOTAL EXPENSES		322,922			290,840			928,040			819,358

Operating loss		(273,422	)		(274,835	)		(799,579	)		(793,881	)

OTHER INCOME/(EXPENSE)
Interest expense		(529,188	)		(377,038	)		(1,487,984	)		(981,341	)
Gain (loss) on extinguishment of convertible notes		10,897			-			(346,395	)		496,645
Change in fair value of derivatives liabilities		(1,614,411	)		(919,147	)		(657,765	)		(14,311,427	)
Total other expense		(2,132,702	)		(1,296,185	)		(2,492,144	)		(14,796,123	)

LOSS BEFORE PROVISION FOR INCOME TAXES		(2,406,124	)		(1,571,020	)		(3,291,723	)		(15,590,004	)

Provision for income taxes		-			-			-			-

NET LOSS	$	(2,406,124	)	$	(1,571,020	)	$	(3,291,723	)	$	(15,590,004	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.03	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED		1,511,896,142			739,239,617			1,182,674,443			519,120,610

	For the Nine Months Ended September 30, 2019			For the Nine Months Ended September 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(3,291,723	)	$	(15,590,004	)
Adjustments to reconcile net loss to net cash from operating activities:
Stock based compensation		-			1,877
Amortization		15,858			15,858
Amortization of debt discounts		1,350,982			878,349
Increase in principal balance due to penalty provision		-			12,500
Change in fair value of derivatives liabilities		657,765			14,311,427
Loss on extinguishment of convertible notes payable		346,395			(496,645	)
Changes in assets and liabilities:
Accounts receivable		(14,900	)		(9,199	)
Accounts payable		(8,039	)		5,765
Accrued expenses		128,001			47,133
Management fee payable		(145,000	)		66,300
Net cash used in operating activities		(960,661	)		(756,639	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on notes payable to related party		(50,000	)		-
Proceeds from notes payable to related party		50,000			-
Payments on convertible notes payable		(194,111	)		(405,294	)
Prepayment premiums paid on convertible notes payable		(38,343	)		(57,004	)
Proceeds from convertible notes payable		1,047,295			1,378,072
Net cash provided from financing activities		814,841			915,774

NET INCREASE (DECREASE) IN CASH		(145,820	)		159,135
BEGINNING CASH BALANCE		304,056			13,697
ENDING CASH BALANCE	$	158,236		$	172,832

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	$	14,357		$	6,712
Cash payments for income taxes	$	-		$	-

NON-CASH FINANCING ACTIVITIES:
Conversion of notes payable, accrued interest and derivative liabilities into common stock	$	3,723,379		$	10,319,680
Conversion of management fees into preferred stock	$	-		$	150,000
Beneficial conversion feature	$	-		$	114,000

	September 30, 2020			December 31, 2019
ASSETS
CURRENT ASSETS
Cash	$	38,706		$	88,648
Accounts receivable		-			5,600
Inventory		-			-
Total Current Assets		38,706			94,248

OTHER ASSETS
Licenses, net of amortization		386,534			436,555
TOTAL ASSETS	$	425,240		$	530,803

LIABILITIES AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
Accounts payable	$	344,451		$	320,785
Accrued expenses		155,573			120,492
Management fee and patent liability - related party		211,282			240,082
Convertible notes payable, net of discount of $288,851 and $560,899, respectively		908,503			1,062,266
Advances from related party		10,800			10,800
Derivative liabilities		1,570,971			6,847,877
Total Current Liabilities		3,201,580			8,602,302

TOTAL LIABILITIES		3,201,580			8,602,302

Commitments and contingencies

STOCKHOLDERS' DEFICIT
Preferred stock, $0.001 par value, 7,000,000 and 7,000,000 shares authorized, no shares issued and outstanding at September 30, 2020 and December 31, 2019		-			-
Series A preferred stock, $0.001 par value, 3,000,000 shares authorized, 3,000,000 shares issued and outstanding at September 30, 2020 and December 31, 2019		3,000			3,000
Common stock, $0.001 par value, 6,000,000,000 shares authorized; 475,741,841 and 22,493,046 issued and 475,737,841 and 22,489,046 outstanding at September 30, 2020 and December 31, 2019, respectively		475,738			22,489
Additional paid-in capital		20,015,160			17,468,018
Accumulated deficit		(23,270,238	)		(25,565,006	)
TOTAL STOCKHOLDERS' DEFICIT		(2,776,340	)		(8,071,499	)

TOTAL LIABILITIES AND STOCKHOLDERS'DEFICIT	$	425,240		$	530,803

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSES CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Nine Months Ended September 30, 2020			For the Nine Months Ended September 30, 2019

CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)	$	2,294,768		$	(3,291,723	)
Adjustments to reconcile net income (loss) to
net cash from operating activities:
Stock-based compensation		68,242			-
Amortization		50,021			15,858
Amortization of debt discounts		804,898			1,350,982
Change in fair value of derivatives liabilities		(3,996,775	)		657,765
Loss on extinguishment of convertible notes payable		-			346,395
Changes in assets and liabilities:
Accounts receivable		5,600			(14,900	)
Inventory		-			-
Accounts payable		23,666			(8,039	)
Accrued expenses		126,838			128,001
Management fee payable		131,200			(145,000	)
Net cash used in operating activities		(491,542	)		(960,661	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Payments on notes payable to related party		-			(50,000	)
Proceeds from notes payable to related party		-			50,000
Payments on convertible notes payable		(17,000	)		(194,111	)
Prepayment premiums paid on convertible notes payable		-			(38,343	)
Proceeds from convertible notes payable		458,600			1,047,295
Net cash provided from financing activities		441,600			814,841

NET DECREASE IN CASH		(49,942	)		(145,820	)
BEGINNING CASH BALANCE		88,648			304,056
ENDING CASH BALANCE	$	38,706		$	158,236

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	$	6,000		$	14,357
Cash payments for income taxes	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of notes payable, accrued interest and derivative liabilitiesinto common stock	$	2,772,149		$	3,723,379
Conversion of management fees and patent liability into common stock	$	160,000		$	-

	Series A Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Capital			Deficit			Deficit
December 31, 2019		3,000,000	$	3,000		22,489,046	$	22,489	$	17,468,018		$	(25,565,006	)	$	(8,071,499	)

Common stock issued for related party management liabilities		-		-		64,314,883		64,315		95,685			-			160,000

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		388,932,620		388,933		644,485			-			1,033,418

Relief of derivative liabilities		-		-		-		-		1,738,731			-			1,738,731

Stock-based compensation		-		-		-		-		68,242			-			68,242

Difference in shares from reverse stock split		-		-		1,292		1		(1	)		-			-

Net income		-		-		-		-		-			2,294,768			2,294,768

September 30, 2020		3,000,000	$	3,000		475,737,841	$	475,738	$	20,015,160		$	(23,270,238	)	$	(2,776,340	)

	Series A Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Capital			Deficit			Deficit
December 31, 2018		3,000,000	$	3,000		902,711,370	$	902,711	$	12,180,985		$	(17,081,333	)	$	(3,994,637	)

Common stock issued for cashless warrant exercise		-		-		79,686,983		79,687		(79,687	)		-			-

Common stock issued for conversion of convertible notes, accrued interest and derivative liabilities		-		-		1,126,075,936		1,126,076		232,012			-			1,358,088

Relief of derivative liabilities		-		-		-		-		2,365,291			-			2,365,291

Net loss		-		-		-		-		-			(3,291,723	)		(3,291,723	)

September 30, 2019		3,000,000	$	3,000		2,108,474,289	$	2,108,474	$	14,698,601		$	(20,373,056	)	$	(3,562,981	)

	Notes			Warrants			Total			Notes			Warrants			Total
Derivative liability at December 31, 2018	$	1,983,828		$	1,243,554		$	3,227,382
Derivative liability at December 31, 2019										$	6,659,055		$	188,822		$	6,847,877
Addition of new conversion option derivatives		1,235,703			87,012			1,322,715			852,523			-			852,523
Extinguishment/modification		(1,454,983	)		(910,308	)		(2,365,291	)		-			-			-
Conversion of note derivatives		631,941			(280,639	)		351,302			(1,738,731	)		-			(1,738,731	)
Change in fair value		47,901			(39,849	)		8,052			(4,274,206	)		(116,492	)		(4,390,698	)
Derivative liability at September 30, 2019	$	2,444,390		$	99,770		$	2,544,160
Derivative liability at September 30, 2020										$	1,498,641		$	72,330		$	1,570,971

	~~Page Number~~

	For the Three Months Ended September 30, 2020		For the Nine Months Ended September 30, 2020
Weighted average common shares outstanding used in calculating basic earnings per share		342,491,367		184,711,652
Effect of warrants		23,891,985		28,156,744
Effect of convertible notes payable		789,553,520		653,863,392
Effect of convertible related party management fee and patent liabilities		206,948,110		206,948,110
Weighted average common shares outstanding used in calculating diluted earnings per share		1,362,884,982		1,073,679,898

Net income as reported	$	394,851	$	2,294,768
Add - Interest on convertible notes payable		28,228		105,338
Net income available to common stockholders	$	423,079	$	2,400,106

	•	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	•	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

	•	Payment may be made in cash or shares of our common at a discount of 30% to the recent trading price.
	•	In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.
	•	For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

For the year ended December 31,

2019		504,990
2020		1,027,624		832,804
2021				364,550
Total	$	1,532,614	$	1,197,354

	Weighted Average Inputs Used

Annual dividend yield	$	-
Expected life (years)		2.8 to 4.8
Risk-free interest rate		1.56	%
Expected volatility		94	%
Common stock price	$	0.0008

	Weighted Average Inputs Used

Annual dividend yield	$	-
Expected life (years)		1.8 to 3.8
Risk-free interest rate		0.11% to 0.16	%
Expected volatility		102.64% to 103.79	%
Common stock price	$	0.0029 to $ 0.0119

Outstanding at December 31, 2019		5,040,927
Issuances		11,630,952
Exercises		-
Anti-Dilution/Modification		29,697,233
Forfeitures/cancellations		-
Outstanding at September 30, 2020		46,369,112
Weighted Average Price at September 30, 2020	$	0.007

Outstanding at December 31, 2018		142,075,119
Issuances	��	36,429,554
Exercises		(89,107,585	)
Anti-Dilution/Modification		68,828,703
Forfeitures/cancellations		(9,698,736	)
Outstanding at September 30, 2019		148,527,055
Weighted Average Price at September 30, 2019	$	0.0027

SEC Ref. No.		Title of Document
31.1		Rule 13a-14(a) Certification by Principal Executive Officer
31.2		Rule 13a-14(a) Certification by Principal Financial Officer
32.1		Section 1350 Certification of Principal Executive Officer
32.2		Section 1350 Certification of Principal Financial Officer
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

	Creative Medical Technology Holdings, Inc.

Date: November ~~14, 2019~~13, 2020	By	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer
		(Principal Executive Officer)

Date: November ~~14, 2019~~13, 2020	By	/s/ Donald Dickerson
		Donald Dickerson, Chief Financial Officer
		(Principal Financial Officer)